Next, we designed a sequential treatment regimen of CXCL16 NAb and STAT1 inhibitor to test possible enhanced efficacy of sensitizing MCT-primed tumor to anti-PD-1 treatment. This evidence concerns the gene STAT1 and neoplasm.